Biomarkers for Preclinical Alzheimer's Disease

ISBN-13: 9781493992553 / Angielski / Miękka / 2019 / 272 str.

Robert Perneczky

Spis treści

Series Preface…

Preface…

Table of Contents…

Contributing Authors…

Part I Alzheimer’s Disease as a Societal Challenge

1. Worldwide Economic Costs and Societal Burden of Dementia

Junfang Xu and Chengxuan Qiu

2. Epidemiology and Risk Factors of Alzheimer’s Disease: A Focus on Diet

Cécilia Samieri

Part II Diagnostic Concepts

3. The Dimensional Structure of Subjective Cognitive Decline

Miguel A. Fernández-Blázquez, Marina Ávila-Villanueva, and Miguel Medina

4. Deriving and Testing the Validity of Cognitive-Reserve Candidates

Yaakov Stern and Christian Habeck

5. Methods for Pathological Classification of Alzheimer’s Disease

Johannes Attems, Kirsty E. McAleese, and Lauren Walker

Part III Established Markers of Pathophysiology and Risk

6. Cerebrospinal Fluid Biomarkers of Preclinical Alzheimer’s Disease

Panagiotis Alexopoulos and Chaido Sirinian

7. Brain Structural Imaging in Alzheimer’s Disease 

Sven Haller, Davide Zanchi, Cristelle Rodriguez, and Panteleimon Giannakopoulos

8. Brain Functional Imaging in Preclinical Alzheimer’s Disease

Peter Häussermann, Thorsten Bartsch, and Oliver Granert

9. Imaging of Brain Amyloid Load in Early Alzheimer’s Disease

Timo Grimmer and Jennifer Grace Perryman

10. Functional EEG Connectivity Alterations in Alzheimer’s Disease

Florian Hatz and Peter Fuhr

Part IV Biomarker Discovery

11. A Selected Reaction Monitoring Protocol for the Measurement of sTREM2 in Cerebrospinal Fluid

Amanda J. Heslegrave, Wendy E. Heywood, Kevin M. Mills, Henrik Zetterberg

12. Soluble Amyloid Precursor Proteins in Blood: Methods and Challenges

Robert Perneczky and Panagiotis Alexopoulos

13. Tau Imaging in Preclinical Alzheimer’s Disease

Paul Edison

14. Retinal Imaging in Early Alzheimer’s Disease

Tom MacGillivray, Sarah McGrory, Tom Pearson, and James Cameron

15. In Vivo Volumetry of the Cholinergic Basal Forebrain

Michel J. Grothe, Ingo Kilimann, Lea Grinberg, Helmut Heinsen, and Stefan Teipel

Part V Patient Benefit and Ethical Considerations

16. Clinical Meaningfulness of Biomarkers Endpoints in Alzheimer’s Disease Research

Kok Pin Ng, Tharick A. Pascoal, Xiaofeng Li, Pedro Rosa-Neto, and Serge Gauthier

17. The Ethics of Biomarker-Based Preclinical Diagnosis of Alzheimer’s Disease

Alexander F. Kurz and Nicola T. Lautenschlager

18. Shared Decision-Making and Important Medical and Social Decisions in the Context of Early Diagnosis of Alzheimer’s Disease

Katharina Bronner and Johannes Hamann

Blurb

This volume discusses the importance of imaging, fluid, and genetic biomarkers in detecting the earliest pre-symptomatic stages of Alzheimer’s disease (AD). The chapters in this book are separated into five parts. Part one explores the reasons why we need improved approaches for early detection and diagnosis of AD. Part two describes clinical and research techniques for preclinical AD diagnosis. Part three looks at the current methods in use to diagnose AD and how they can also be used for early detection in healthy older individuals. Parts four and five talk about technological advancements in AD diagnosis and ethical considerations in AD research. In Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory.

Comprehensive and cutting-edge, Biomarkers for Preclinical Alzheimer’s Disease is a valuable resource for individuals interested in the use of biomarker strategies to improve early AD detection. This book will be of great interest to researchers and clinicians from both academia and industry.